{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:48Z","timestamp":1787313888059,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG018440"],"award-info":[{"award-number":["AG018440"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG072053"],"award-info":[{"award-number":["AG072053"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG073979"],"award-info":[{"award-number":["AG073979"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30-AG066530"],"award-info":[{"award-number":["P30-AG066530"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P30NS047101"],"award-info":[{"award-number":["P30NS047101"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.nbd.2023.106285","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T09:37:08Z","timestamp":1694252228000},"page":"106285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce \u03b1-synuclein in a mouse model of Alzheimer's disease"],"prefix":"10.1016","volume":"186","author":[{"given":"Andr\u00e9 D.G.","family":"Leit\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rijwan U.","family":"Ahammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2023.106285_bb0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1089\/hum.2016.017","article-title":"Gene therapy strategies for Alzheimer\u2019s disease: an overview","volume":"27","author":"Alves","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.nbd.2023.106285_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood\u2013brain barrier to blood\u2013brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2023.106285_bb0015","first-page":"1113","article-title":"Delivery across the blood-brain barrier of antisense directed against amyloid \u03b2: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein","volume":"297","author":"Banks","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2023.106285_bb0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/nar\/gkj439","article-title":"Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging","volume":"34","author":"Bartlett","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.nbd.2023.106285_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105172","article-title":"What are activated and reactive glia and what is their role in neurodegeneration?","volume":"148","author":"Bennett","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bbapap.2010.04.001","article-title":"Molecular mechanism of Thioflavin-T binding to amyloid fibrils","volume":"1804","author":"Biancalana","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Proteins Proteome"},{"key":"10.1016\/j.nbd.2023.106285_bb0035","first-page":"1","article-title":"Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity","volume":"12","author":"Bido","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2023.106285_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.nbd.2015.03.003","article-title":"Glia and alpha-synuclein in neurodegeneration: a complex interaction","volume":"85","author":"Br\u00fcck","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3233\/JAD-142844","article-title":"Impact of CRFR1 ablation on amyloid-\u03b2 production and accumulation in a mouse model of Alzheimer\u2019s disease","volume":"45","author":"Campbell","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0050","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2023.106285_bb0055","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","article-title":"Confluence of \u03b1-synuclein, tau, and \u03b2-amyloid pathologies in dementia with Lewy bodies","volume":"72","author":"Colom-Cadena","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2023.106285_bb0060","first-page":"166","article-title":"Antisense oligonucleotide reverses tau pathology","volume":"16","author":"Crunkhorn","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2023.106285_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41593-021-00951-0","article-title":"Microglia contribute to the propagation of A\u03b2 into unaffected brain tissue","volume":"25","author":"d\u2019Errico","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2023.106285_bb0070","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2017.05.001","article-title":"Tau at the crossroads between neurotoxicity and neuroprotection","volume":"94","author":"DeVos","year":"2017","journal-title":"Neuron."},{"key":"10.1016\/j.nbd.2023.106285_bb0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.nbd.2023.106285_bb0080","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","article-title":"The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies","volume":"14","author":"Ferman","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2023.106285_bb0085","first-page":"983","article-title":"Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain","volume":"152","author":"Funato","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2023.106285_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104957","article-title":"Glia in neurodegeneration: drivers of disease or along for the ride?","volume":"142","author":"Gleichman","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.23455","article-title":"Glia: initiators and progressors of pathology in Parkinson\u2019s disease","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2023.106285_bb0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using \u03b1-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol."},{"key":"10.1016\/j.nbd.2023.106285_bb0105","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.nbd.2023.106285_bb0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm0198-097","article-title":"Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes","volume":"4","author":"Holcomb","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2023.106285_bb0115","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11357-016-9929-7","article-title":"Characterization of AD-like phenotype in aged APPSwe\/PS1dE9 mice","volume":"38","author":"Huang","year":"2016","journal-title":"Age."},{"key":"10.1016\/j.nbd.2023.106285_bb0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1389-0344(01)00067-3","article-title":"Co-expression of multiple transgenes in mouse CNS: a comparison of strategies","volume":"17","author":"Jankowsky","year":"2001","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.nbd.2023.106285_bb0125","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/mt.2015.232","article-title":"Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson\u2019s disease and other brain disorders","volume":"24","author":"Javed","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2023.106285_bb0130","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1100\/2011\/371893","article-title":"Interaction between\u202f?-Synuclein and other proteins in neurodegenerative disorders","volume":"11","author":"Jellinger","year":"2011","journal-title":"TheScientificWorldJournal."},{"key":"10.1016\/j.nbd.2023.106285_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106883","article-title":"Cross dimerization of amyloid-\u03b2 and \u03b1Synuclein proteins in aqueous environment: a molecular dynamics simulations study","volume":"9","author":"Jose","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2023.106285_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuint.2008.08.004","article-title":"\u03b1-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC12 cells","volume":"53","author":"Kazmierczak","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.nbd.2023.106285_bb0145","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia","volume":"25","author":"Keiser","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2023.106285_bb0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-pharmtox-010814-124852","article-title":"Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier","volume":"55","author":"Lajoie","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.nbd.2023.106285_bb0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","article-title":"Cortical \u03b1-synuclein load is associated with amyloid-\u03b2 plaque burden in a subset of Parkinson\u2019s disease patients","volume":"115","author":"Lashley","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2023.106285_bb0160","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1261\/rna.5239604","article-title":"In vivo activity of nuclease-resistant siRNAs","volume":"10","author":"Layzer","year":"2004","journal-title":"Rna."},{"key":"10.1016\/j.nbd.2023.106285_bb0165","first-page":"1","article-title":"Phosphorylation induces distinct alpha-synuclein strain formation","volume":"6","author":"Ma","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2023.106285_bb0170","article-title":"Utilization of APPswe\/PS1dE9 transgenic mice in research of Alzheimer's disease: focus on gene therapy and cell-based therapy applications","volume":"2011","author":"Malm","year":"2011","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0175","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s11064-006-9140-9","article-title":"Interaction between A\u03b2 peptide and \u03b1 synuclein: molecular mechanisms in overlapping pathology of Alzheimer\u2019s and Parkinson\u2019s in dementia with Lewy body disease","volume":"31","author":"Mandal","year":"2006","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.nbd.2023.106285_bb0180","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2019.08.005","article-title":"Alzheimer\u2019s disease and other neurodegenerative dementias in comorbidity: a clinical and neuropathological overview","volume":"73","author":"Matej","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.nbd.2023.106285_bb0185","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2023.106285_bb0190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2023.106285_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neurobiolaging.2004.05.010","article-title":"Glia and their cytokines in progression of neurodegeneration","volume":"26","author":"Mrak","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2023.106285_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0006-8993(03)02361-8","article-title":"Astrocytes accumulate A\u03b242 and give rise to astrocytic amyloid plaques in Alzheimer disease brains","volume":"971","author":"Nagele","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2023.106285_bb0205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.neurobiolaging.2004.01.007","article-title":"Contribution of glial cells to the development of amyloid plaques in Alzheimer\u2019s disease","volume":"25","author":"Nagele","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2023.106285_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u03b2-amyloid occurs within the default-mode network and concurrently affects brain connectivity","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2023.106285_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-6-45","article-title":"Microglial phagocytosis induced by fibrillar \u03b2-amyloid is attenuated by oligomeric \u03b2-amyloid: implications for Alzheimer\u2019s disease","volume":"6","author":"Pan","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2023.106285_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-021-01180-z","article-title":"Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer\u2019s disease","volume":"9","author":"Park","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2023.106285_bb0225","first-page":"83","article-title":"Multiple comorbid neuropathologies in the setting of Alzheimer\u2019s disease neuropathology and implications for drug development","volume":"3","author":"Rabinovici","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.nbd.2023.106285_bb0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1601-183X.2006.00221.x","article-title":"Impaired spatial learning in the APPSwe+ PSEN1\u0394E9 bigenic mouse model of Alzheimer\u2019s disease","volume":"6","author":"Reiserer","year":"2007","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.nbd.2023.106285_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171925","article-title":"\u03b1-Synuclein increases \u03b2-amyloid secretion by promoting \u03b2\u2212\/\u03b3-secretase processing of APP","volume":"12","author":"Roberts","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2023.106285_bb0240","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jnen\/63.5.418","article-title":"Amyloid-\u03b2 deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP\/PS1 mice","volume":"63","author":"Sadowski","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2023.106285_bb0245","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0002-9440(10)63235-X","article-title":"Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer\u2019s disease","volume":"164","author":"Schmitz","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.nbd.2023.106285_bb0250","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood\u2013brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2023.106285_bb0255","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/mt.2014.129","article-title":"ESCRT-mediated uptake and degradation of brain-targeted \u03b1-synuclein single chain antibody attenuates neuronal degeneration in vivo","volume":"22","author":"Spencer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2023.106285_bb0260","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1523\/JNEUROSCI.0775-16.2016","article-title":"Reducing endogenous \u03b1-synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer\u2019s disease transgenic mouse model","volume":"36","author":"Spencer","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2023.106285_bb0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/hmg\/ddv633","article-title":"\u03b1-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease","volume":"25","author":"Spencer","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2023.106285_bb0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2019.03.001","article-title":"Systemic peptide mediated delivery of an siRNA targeting \u03b1-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease","volume":"127","author":"Spencer","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0275","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/brain\/awab099","article-title":"Comorbid neuropathological diagnoses in early versus late-onset Alzheimer\u2019s disease","volume":"144","author":"Spina","year":"2021","journal-title":"Brain."},{"key":"10.1016\/j.nbd.2023.106285_bb0280","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2023.106285_bb0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-Synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2023.106285_bb0290","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1073\/pnas.96.12.7053","article-title":"Peptide nucleic acids targeted to the neurotensin receptor and administered ip cross the blood\u2013brain barrier and specifically reduce gene expression","volume":"96","author":"Tyler","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2023.106285_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-019-0172-x","article-title":"Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities","volume":"8","author":"Visanji","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.nbd.2023.106285_bb0300","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1194653","article-title":"Tau reduction prevents A\u03b2-induced defects in axonal transport","volume":"330","author":"Vossel","year":"2010","journal-title":"Science."},{"key":"10.1016\/j.nbd.2023.106285_bb0305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3233\/JAD-141722","article-title":"Corticotropin-releasing factor Receptor-1 antagonism reduces oxidative damage in an Alzheimer\u2019s disease transgenic mouse model","volume":"45","author":"Zhang","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2023.106285_bb0310","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jalz.2015.09.007","article-title":"Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer\u2019s disease","volume":"12","author":"Zhang","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2023.106285_bb0315","doi-asserted-by":"crossref","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123003005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996123003005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:56:59Z","timestamp":1729126619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996123003005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":63,"alternative-id":["S0969996123003005"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106285","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce \u03b1-synuclein in a mouse model of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2023.106285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106285"}}